TD-1792 is an investigational glycopeptide-cephalosporin heterodimer antibiotic for the treatment of Gram-positive infections. We are partnered with R-Pharm on the development and commercialization of TD-1792. R-Pharm is conducting a Phase 3 clinical study of TD-1792 in complicated skin and soft tissues infections (cSSSI), caused by gram-positive bacteria.
TD-6450 is a multivalent NS5A inhibitor. We have a licensing agreement with Trek Therapeutics for an exclusive worldwide license for the development, manufacturing, use and commercial sale of TD-6450 as a component in combination hepatitis C virus products. Trek Therapeutics is conducting a Phase 2a clinical study to evaluate TD-6450 in combination with faldaprevir and ribavirin in patients infected with HCV genotype 4.
TD-1607 is an investigational glycopeptide-cephalosporin heterodimer antibiotic for the treatment of Gram-positive infections. It is structurally distinct from TD-1792 but demonstrates a similar potent and rapidly bactericidal profile in vitro.